Jeanne Eagels

ENERGY TRANSFER ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Energy Transfer LP and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 7, 2022
Legal, Professional Services, Transfer, HDD, Energy, District court, Tuscarawas, NGL, Partnership, Enforcement, Transport, Complaint, Court, Jeanne Eagels, News, Telephone, Energy Transfer Partners, Federal Energy Regulatory Commission, FERC, Natural gas, Master limited partnership, NYSE, SEC, Form 10-Q, Tuscarawas River, P.C, Person, Oil

Investors have until August 2, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 2, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Energy Transfer is a Delaware company headquartered in Dallas, Texas.
  • Energy Transfer is a company engaged in natural gas and propane pipeline transport.
  • The Partnership through its subsidiaries provides transportation, storage, and terminalling services for products like natural gas, crude oil, NGL, and refined products.

DENTSPLY SIRONA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Dentsply Sirona, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 7, 2022
Legal, Professional Services, Percussion section, District court, Company, Audit committee, Anesthetic, Court, Jeanne Eagels, Telephone, Degenerative disease, XRAY, Plaque, NASDAQ, Board, Lists of schools in England, P.C, Person, Property management

Investors have until August 1, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 1, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Dentsply is a dental equipment manufacturer with offices across the United States.
  • Dentsply produces a wide array of dental supplies, ranging from anesthetics, plaque and gum disease prevention, tooth polishers, and artificial teeth.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.

COGNYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Cognyte Software Ltd. on Behalf of Cognyte Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 7, 2022
Legal, Professional Services, Jeanne Eagels, News, Telephone, Company, P.C, NASDAQ, Private investigator

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cognyte Software Ltd. (Cognyte or the Company) (NASDAQ: CGNT) on behalf of Cognyte stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cognyte Software Ltd. (Cognyte or the Company) (NASDAQ: CGNT) on behalf of Cognyte stockholders.
  • Our investigation concerns whether Cognyte has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Cognyte's stock fell $3.63, or 31.1%, to close at $8.03 per share on April 5, 2022, thereby injuring investors.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

APYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Apyx Medical Corporation and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 7, 2022
Legal, Professional Services, Energy Products Inc, District court, Company, Advanced Energy, Food, Court, Jeanne Eagels, News, Telephone, Coagulation, FDA, Defendant, NASDAQ, Lists of schools in England, P.C, Regulation of tobacco by the U.S. Food and Drug Administration, Person, Risk management

Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On March 14, 2022, Apyx disclosed that the U.S. Food and Drug Administration (FDA) would be posting a Medical Device Safety Communication (MDSC) related to the Companys Advanced Energy Products.
  • On this news, the Companys stock fell $4.02, or 40.6%, to close at $5.88 per share on March 14, 2022, on unusually heavy trading volume.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

PLAYSTUDIOS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Playstudios, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 4, 2022
Legal, Professional Services, District court, Company, Court, Jeanne Eagels, Class, Telephone, SPAC, NASDAQ, P.C, Person, Security (finance)

Investors have until June 6, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 6, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Playstudios repeatedly communicated to the market that its game Kingdom Boss was on track for a 2021 release throughout that year.
  • As a result of defendants' wrongful conduct, Class members paid artificially inflated prices for their Playstudios securities and suffered substantial losses and damages.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

IBM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against International Business Machines Corporation and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 4, 2022
Legal, Professional Services, Cloud, District court, Company, Complaint, IBM, Court, Jeanne Eagels, News, Securities Exchange Act of 1934, Telephone, Defendant, NYSE, Lists of schools in England, P.C, Person, Private investigator

Investors have until June 6, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 6, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Unbeknownst to the investing public, the Company had stopped and/or curtailed its improper conduct described below, which caused Company results to suffer.
  • The defendants in the case are IBM, Virginia M. Rometty, Martin J. Schroeter, James J. Kavanaugh and Arvind Krishna.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

ABBVIE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against AbbVie, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 4, 2022
Legal, Professional Services, Janus, District court, Company, Adalimumab, RA, Food, Pressure, Court, Jeanne Eagels, News, Telephone, FDA, JAK, Cancer, Defendant, AbbVie, Risk, Review, NYSE, Rheumatoid arthritis, ABBV, Lists of schools in England, Pfizer, P.C, Regulation of tobacco by the U.S. Food and Drug Administration, Person, Safety, Pharmaceutical industry, Medical device, Tofacitinib, Upadacitinib

Investors have until June 6, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 6, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The company's revenues will come under significant pressure in the coming years when its best-selling drug, Humira, will lose patent protection in 2023.
  • Accordingly, AbbVie's future revenue and earnings depend in large part on its ability to develop new sources of revenue to offset Humira's lost sales.
  • Rinvoqan anti-inflammatory drug manufactured by AbbVie and used to treat rheumatoid arthritis (RA) and other diseases by inhibiting Janus kinase (JAK) enzymeswas touted as one such drug.

NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, June 3, 2022
Legal, Professional Services, Food, News, Jeanne Eagels, Telephone, P.C, NVS, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Novartis, Website, Private investigator

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (Novartis or the Company) (NYSE: NVS) on behalf of Novartis stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (Novartis or the Company) (NYSE: NVS) on behalf of Novartis stockholders.
  • Our investigation concerns whether Novartis has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On May 5, 2022, Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey.
  • On this news, Novartis stock fell $2.06, or 2.3%, to close at $86.21 on May 5, 2022, thereby injuring investors.

NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 2, 2022
Legal, Professional Services, Food, News, Jeanne Eagels, Telephone, P.C, NVS, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Novartis, Website, Private investigator

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (Novartis or the Company) (NYSE: NVS) on behalf of Novartis stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (Novartis or the Company) (NYSE: NVS) on behalf of Novartis stockholders.
  • Our investigation concerns whether Novartis has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On May 5, 2022, Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey.
  • On this news, Novartis stock fell $2.06, or 2.3%, to close at $86.21 on May 5, 2022, thereby injuring investors.

SPERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 2, 2022
Legal, Professional Services, New Drug Application, District court, Company, HBR, Infection, Food, Court, Jeanne Eagels, Complicated, News, Telephone, Treatment, Workforce, FDA, Patient, Urinary tract infection, Review, Tebipenem, NASDAQ, Population, Lists of schools in England, NDA, Degenerative disease, P.C, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

Investors have until July 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Spero, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.